NEW YORK (GenomeWeb News) – CombiMatrix today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholders' equity.

The Director of Listing Qualifications informed the Irvine, Calif.-based firm of its compliance in a letter dated Aug. 20, saying that based on CombiMatrix's Form 10-Q for the second quarter, which indicated that it had stockholders' equity of $5.7 million, the Nasdaq staff determined that the company was in compliance and "the matter is now closed."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.